Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1608961 | 0.84 | PDE10A (0.35) | — | |
| SCHEMBL1608762 | 0.78 | COMT (0.37) | — | |
| SCHEMBL1609695 | 0.73 | STING1 (0.37) | — | |
| SCHEMBL2403696 | 0.69 | ALDH1A1 (0.34) | — | |
| SCHEMBL5055418 | 0.66 | AR (0.38) | — | |
| SCHEMBL28713607 | 0.66 | TRPM8 (0.46) | — | |
| SCHEMBL947450 | 0.63 | DRD2 (0.37) | — | |
| SCHEMBL2540747 | 0.63 | CYP1A2 (0.35) | — | |
| SCHEMBL1609283 | 0.63 | GPR35 (0.56) | GPR35 | |
| SCHEMBL295269 | 0.62 | CNR2 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318785-B2 | Pharmaceutical compounds | ORION CORPORATION (FI) | 2012-11-27 | — | — | US | disclosed |
| US-20110086852-A2 | PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2011-04-14 | — | — | US | disclosed |
| EP-1910325-B1 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORP (FI) | 2010-10-06 | — | — | EP | disclosed |
| US-20090209532-A1 | PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2009-08-20 | — | — | US | disclosed |
| EP-1910325-A2 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007010085-A2 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209532-A1 | PHARMACEUTICAL COMPOUNDS | COMT, CYP2C19, UGT1A1 | GPR35 1268/4885 |
| US-20110086852-A2 | PHARMACEUTICAL COMPOUNDS | COMT, CYP2C19, CYP3A4 | GPR35 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.